FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043955534> ?p ?o ?g. }

• W2043955534 endingPage "550" @default.
• W2043955534 startingPage "538" @default.
• W2043955534 abstract "In Brief Objective: Lymphatic mapping and sentinel lymphadenectomy (LM/SL) have been applied to virtually all solid neoplasms since our original description of LM/SL for melanoma. Our objectives were to determine the diagnostic and therapeutic utility of LM/SL, investigate carbon dye for mapping the microanatomy of lymphatic flow within the sentinel node (SN), and determine the prognostic accuracy of molecular assessment of the SN. Methods: Since 1985, 1599 patients with AJCC Stage I/II melanoma have been treated by LM/SL at our institution and 4590 have been treated by wide excision (WE) without nodal staging. We examined the incidence of clinical nodal recurrence after WE alone, the incidence of subclinical nodal metastases found by LM/SL, and the incidence of nodal recurrence in basins with histopathology-negative SNs. Results: In 1514 LM/SL patients with a primary of known Breslow thickness, the incidence of metastasis in nodes claimed to be sentinel was 7.3%, 19.7%, 33.2%, and 39.7% for primary lesions ≤1.0, 1.01–2.0, 2.01–4.0, and >4.0 mm, respectively. In 3652 WE-only patients, the corresponding rates of nodal recurrence were 12.0%, 32.0%, 34.4%, and 30.1%. Thus, LM/SL detected only 60% of expected nodal metastases from primary melanomas <2.01 mm. Forty of 1599 (3.1%) patients developed recurrence in basins with immunohistochemistry (IH)-negative SNs. To determine whether nonrandom intranodal distribution of tumor cells could explain missed SN metastases, we coinjected carbon particles and blue dye during LM/SL in 166 patients: 25 (16%) patients had nodal metastases, all of which were found only in nodal subsectors containing carbon particles. When paraffin-embedded SNs from a subset of 162 IH-negative patients were re-examined by quantitative multimarker reverse-transcriptase polymerase chain reaction (qRT) assay, 49 (30%) gave positive signals. These patients had a significantly higher risk of disease recurrence and death than did patients whose IH and qRT results were negative (p < 0.0001). Comparison of 287 prognostically matched pairs of patients who underwent immediate (after LM/SL) versus delayed (after observation) dissection of nodal metastases revealed 5-, 10-, and 15-year survival rates of 73%, 69%, and 69% versus 51%, 37%, and 32%, respectively (P ≤ 0.001). Conclusions: SN assessment based on intranodal compartmentalization of lymphatic flow (carbon dye mapping) should increase the accuracy of IH and, in combination with multimarker qRT assessment, will allow confident identification of most patients for whom surgery alone is curative. Our data suggest a significant therapeutic benefit for immediate dissection based on identification of a tumor-involved SN. Sentinel node assessment based on the intranodal comparmentalization of lymphatic flow and on multimarker molecular as well as immunohistochemical techniques increases the accuracy of lymphatic mapping and allows confident identification of patients for whom surgery is likely to be curative without adjuvant therapy." @default.
• W2043955534 created "2016-06-24" @default.
• W2043955534 creator A5000113684 @default.
• W2043955534 creator A5008106546 @default.
• W2043955534 creator A5016886577 @default.
• W2043955534 creator A5025558951 @default.
• W2043955534 creator A5025850876 @default.
• W2043955534 creator A5029428307 @default.
• W2043955534 creator A5031036955 @default.
• W2043955534 creator A5032101112 @default.
• W2043955534 creator A5034641530 @default.
• W2043955534 creator A5042476500 @default.
• W2043955534 creator A5049324725 @default.
• W2043955534 creator A5070009002 @default.
• W2043955534 creator A5070990818 @default.
• W2043955534 creator A5080451117 @default.
• W2043955534 date "2003-10-01" @default.
• W2043955534 modified "2023-10-17" @default.
• W2043955534 title "Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma" @default.
• W2043955534 cites W1573148785 @default.
• W2043955534 cites W1906398111 @default.
• W2043955534 cites W1964254161 @default.
• W2043955534 cites W1964478633 @default.
• W2043955534 cites W1965643834 @default.
• W2043955534 cites W1973718469 @default.
• W2043955534 cites W1986793246 @default.
• W2043955534 cites W1997817818 @default.
• W2043955534 cites W2001598338 @default.
• W2043955534 cites W2007807118 @default.
• W2043955534 cites W2020873956 @default.
• W2043955534 cites W2023973053 @default.
• W2043955534 cites W2033124322 @default.
• W2043955534 cites W2036366652 @default.
• W2043955534 cites W2039110392 @default.
• W2043955534 cites W2042718938 @default.
• W2043955534 cites W2042921773 @default.
• W2043955534 cites W2045166186 @default.
• W2043955534 cites W2052280998 @default.
• W2043955534 cites W2056130168 @default.
• W2043955534 cites W2056906032 @default.
• W2043955534 cites W2067274296 @default.
• W2043955534 cites W2080404550 @default.
• W2043955534 cites W2141685284 @default.
• W2043955534 cites W2143422545 @default.
• W2043955534 cites W2256813717 @default.
• W2043955534 cites W2397506584 @default.
• W2043955534 cites W32697732 @default.
• W2043955534 doi "https://doi.org/10.1097/01.sla.0000086543.45557.cb" @default.
• W2043955534 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1360112" @default.
• W2043955534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14530725" @default.
• W2043955534 hasPublicationYear "2003" @default.
• W2043955534 type Work @default.
• W2043955534 sameAs 2043955534 @default.
• W2043955534 citedByCount "248" @default.
• W2043955534 countsByYear W20439555342012 @default.
• W2043955534 countsByYear W20439555342013 @default.
• W2043955534 countsByYear W20439555342014 @default.
• W2043955534 countsByYear W20439555342015 @default.
• W2043955534 countsByYear W20439555342016 @default.
• W2043955534 countsByYear W20439555342017 @default.
• W2043955534 countsByYear W20439555342018 @default.
• W2043955534 countsByYear W20439555342019 @default.
• W2043955534 countsByYear W20439555342020 @default.
• W2043955534 countsByYear W20439555342021 @default.
• W2043955534 countsByYear W20439555342022 @default.
• W2043955534 countsByYear W20439555342023 @default.
• W2043955534 crossrefType "journal-article" @default.
• W2043955534 hasAuthorship W2043955534A5000113684 @default.
• W2043955534 hasAuthorship W2043955534A5008106546 @default.
• W2043955534 hasAuthorship W2043955534A5016886577 @default.
• W2043955534 hasAuthorship W2043955534A5025558951 @default.
• W2043955534 hasAuthorship W2043955534A5025850876 @default.
• W2043955534 hasAuthorship W2043955534A5029428307 @default.
• W2043955534 hasAuthorship W2043955534A5031036955 @default.
• W2043955534 hasAuthorship W2043955534A5032101112 @default.
• W2043955534 hasAuthorship W2043955534A5034641530 @default.
• W2043955534 hasAuthorship W2043955534A5042476500 @default.
• W2043955534 hasAuthorship W2043955534A5049324725 @default.
• W2043955534 hasAuthorship W2043955534A5070009002 @default.
• W2043955534 hasAuthorship W2043955534A5070990818 @default.
• W2043955534 hasAuthorship W2043955534A5080451117 @default.
• W2043955534 hasBestOaLocation W20439555342 @default.
• W2043955534 hasConcept C120665830 @default.
• W2043955534 hasConcept C121332964 @default.
• W2043955534 hasConcept C121608353 @default.
• W2043955534 hasConcept C126322002 @default.
• W2043955534 hasConcept C126838900 @default.
• W2043955534 hasConcept C142724271 @default.
• W2043955534 hasConcept C146357865 @default.
• W2043955534 hasConcept C151730666 @default.
• W2043955534 hasConcept C179671157 @default.
• W2043955534 hasConcept C181152851 @default.
• W2043955534 hasConcept C2777658100 @default.
• W2043955534 hasConcept C2779013556 @default.
• W2043955534 hasConcept C2780212769 @default.
• W2043955534 hasConcept C2780824555 @default.
• W2043955534 hasConcept C2780849966 @default.
• W2043955534 hasConcept C2908643394 @default.

• next